Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.80 | — | — | — | — | — | — | — | 0.68 | — | — | — | — | — | — | 2.24 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 37.63 | 12.33 | 23.96 | 19.88 | 45.30 | 38.68 | 48.23 | 43.76 | 72.41 | 71.08 | 50.33 | 43.81 | 46.67 | 58.65 | 56.58 | 89.24 | 110.28 | 54.41 | 477.20 | — | — |
| — | -68.1% | -50.3% | -54.6% | -37.4% | -45.6% | -4.2% | -0.1% | +55.2% | +21.2% | -11.0% | -50.9% | -57.7% | +7.8% | -88.1% | — | — | — | — | — | — | |
| P/B Ratio | 1.66 | 2.15 | 1.79 | 1.33 | 1.82 | 1.41 | 1.15 | 1.22 | 1.60 | 3.71 | 2.22 | 1.53 | 1.56 | 1.63 | 1.22 | 1.40 | 1.48 | 1.08 | 1.32 | 1.38 | 1.89 |
| — | +52.9% | +56.2% | +9.2% | +13.9% | -62.1% | -48.2% | -20.6% | +2.5% | +127.1% | +81.0% | +9.8% | +5.4% | +51.1% | -6.9% | +1.1% | -21.8% | -44.7% | -15.9% | -81.6% | -62.5% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | 0.60 | — | — | — | — | — | — | 10.16 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.7% | 93.3% | 87.1% | 84.2% | 76.3% | 76.2% | 72.9% | 88.3% | 91.3% | 64.2% | 75.9% | 72.0% | 91.4% | 17.0% | 11.7% | -11.1% | -42.5% | 6.7% | -531.4% | — | — |
| — | +22.4% | +19.4% | -4.5% | -16.4% | +18.8% | -3.9% | +22.6% | -0.2% | +277.1% | +547.8% | +746.5% | +315.1% | +154.6% | +102.2% | — | — | — | — | — | — | |
| Operating Margin | -873.9% | -247.1% | -530.3% | -608.9% | -907.4% | -1020.1% | -1222.0% | -1165.3% | -1146.9% | -1228.3% | -1124.3% | -1496.2% | -1363.7% | -1396.0% | -1615.5% | -2301.0% | -2590.7% | -1749.2% | -12156.9% | — | — |
| — | +75.8% | +56.6% | +47.7% | +20.9% | +16.9% | -8.7% | +22.1% | +15.9% | +12.0% | +30.4% | +35.0% | +47.4% | +20.2% | +86.7% | — | — | — | — | — | — | |
| Net Margin | -764.0% | -225.1% | -477.7% | -541.1% | -803.1% | -899.4% | -1023.3% | -899.6% | 10574.7% | -1115.7% | -995.8% | -1350.7% | -1234.3% | -1248.6% | -1444.4% | 847.5% | -2325.0% | -1644.7% | -11391.1% | — | — |
| — | +75.0% | +53.3% | +39.8% | -107.6% | +19.4% | -2.8% | +33.4% | +956.8% | +10.6% | +31.1% | -259.4% | +46.9% | +24.1% | +87.3% | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -30.2% | -9.4% | -8.6% | -8.7% | -7.8% | -7.9% | -5.9% | -6.1% | 82.9% | -13.7% | -10.5% | -11.3% | -9.9% | -8.4% | -7.6% | 3.4% | -7.5% | -7.9% | -7.6% | -7.0% | -5.7% |
| — | -19.4% | -45.0% | -43.1% | -109.4% | +42.3% | +43.4% | +46.1% | +940.1% | -63.4% | -38.4% | -432.8% | -31.2% | -6.4% | +0.0% | +148.2% | -32.9% | -89.7% | +13.5% | +68.3% | +70.3% | |
| ROA | -27.9% | -8.8% | -8.0% | -8.1% | -7.2% | -7.4% | -5.5% | -5.6% | 73.9% | -11.8% | -9.1% | -9.9% | -8.7% | -7.5% | -6.8% | 3.0% | -6.7% | -7.1% | -6.8% | -6.4% | -5.2% |
| — | -18.6% | -43.9% | -44.1% | -109.8% | +37.5% | +39.2% | +43.4% | +946.8% | -58.1% | -34.6% | -426.8% | -29.9% | -5.6% | +0.8% | +147.5% | -30.2% | -85.5% | +3.4% | +42.7% | +50.9% | |
| ROIC | -26.6% | -8.3% | -7.6% | -7.7% | -6.8% | -6.9% | -5.4% | -6.3% | -7.4% | -11.9% | -9.3% | -9.4% | -8.2% | -7.1% | -6.6% | -7.2% | -6.4% | -6.2% | -6.3% | -6.9% | -7.0% |
| — | -21.5% | -40.5% | -20.7% | +8.4% | +42.3% | +41.8% | +32.6% | +8.8% | -67.0% | -40.8% | -30.7% | -27.9% | -14.2% | -4.6% | -4.5% | +9.2% | +37.7% | +59.0% | +57.2% | +42.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.10 | 0.09 | 0.09 | 0.09 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 |
| — | -14.7% | -10.7% | -8.9% | -7.3% | -63.6% | -60.7% | -58.3% | -56.1% | +19.5% | +15.7% | +14.1% | +0.5% | +0.9% | +1.4% | +3.5% | +19.1% | +37.0% | +73.7% | -71.5% | -68.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 11.46 | 10.22 | 14.19 | 11.46 | 13.82 | 14.48 | 18.50 | 11.90 | 8.99 | 10.09 | 12.84 | 12.27 | 12.06 | 13.73 | 17.55 | 13.30 | 14.65 | 17.98 | 21.30 | 17.79 | 22.55 |
| — | -29.4% | -23.3% | -3.7% | +53.7% | +43.5% | +44.1% | -3.0% | -25.4% | -26.5% | -26.8% | -7.7% | -17.7% | -23.6% | -17.6% | -25.3% | -35.0% | -36.0% | -12.7% | +163.7% | +135.1% | |
| Quick Ratio | 11.06 | 9.79 | 13.59 | 11.06 | 13.39 | 14.04 | 17.93 | 11.56 | 8.77 | 9.71 | 12.39 | 11.99 | 11.76 | 13.45 | 17.30 | 13.16 | 14.55 | 17.89 | 21.24 | 17.79 | 22.55 |
| — | -30.3% | -24.2% | -4.3% | +52.7% | +44.6% | +44.7% | -3.6% | -25.4% | -27.8% | -28.4% | -8.9% | -19.2% | -24.8% | -18.6% | -26.0% | -35.5% | -36.3% | -13.0% | +163.7% | +139.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AGIO stock.
Agios Pharmaceuticals, Inc.'s current P/E is -4.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Agios Pharmaceuticals, Inc.'s current operating margin is -873.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Agios Pharmaceuticals, Inc.'s business trajectory between earnings reports.